CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine
PLOS One · 2025
DOI: 10.1371/journal.pone.0322918 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Martin Kamilo Angwe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, College of Health Science, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Artemether, Lumefantrine Drug Combination, Polymorphism, Single Nucleotide, Antimalarials, Malaria, Falciparum. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, National Institutes of Health, European and Developing Countries Clinical Trials Partnership.
Abstract (Originalsprache)
CYP2B6 , one of the most polymorphic enzymes, plays a major role in the metabolism of artemisinin and its derivatives. Variation in the frequency of the most common, yet functionally deficient CYP2B6*6 allele may impact artemisinin exposure, potentially contributing to differences in treatment outcomes . This study assessed the prevalence of the CYP2B6*6 genotype among patients with uncomplicated malaria treated with artemether-lumefantrine at Adjumani District Hospital in the West Nile region, Uganda. A total of 100 randomly selected patients with microscopically confirmed uncomplicated P. falciparum malaria receiving artemether-lumefantrine (AL) were included in the study. Blood samples, 2−3 mL each, were collected using EDTA tubes on days 0 and 3 after AL administration. DNA was extracted using Qiagen DNA Mini kit. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used to determine the CYP2B6*6 genotype of the participants. P. falciparum positivity was determined by microscopy and qPCR. For qPCR, parasite clearance was determined using comparative CT value. Data analysis was done using STATA ver 17.0 at a 95% significance level. Among the malaria patients genotyped, 65% were female, and 35% were male, with a mean age of 17 ± 10 years. The CYP2B6*6 variant allele frequency was 0.37, and the genotype frequency was 43% GG, 17% TT and 40% GT. P. falciparum day 3 microscopy positivity was 14% (6/43) among the GG, 37.5% (15/40) among the GT, and 17.64% (3/17) among the TT patients. PCR positivity rates were 58.1% (25/43) in the GG, 72.5% (29/40) in the GT, and 52.9% (9/17) in the TT patients. Heterozygous individuals (GT) had slow parasite clearance by a 10-fold difference compared to the homozygous (GG, TT) individuals ( U = 323.0; Z = −2.3442; p = 0.019). Malaria patients in Adjumani district had a high frequency of the CYP2B6*6 variant allele. Interindividual variability in P. falciparum clearance exists, with heterozygous patients demonstrating slow artemether-lumefantrine P. falciparum parasite clearance. There is a need to consider incorporating host genomic factors, such as metabolising enzyme genotype into routine Therapeutic Efficacy Studies (TES).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, College of Health Science, Makerere University, Kampala, Uganda.
- Research Centre for Tropical Diseases and Vector Control, School of Veterinary Medicine and Animal Resources, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda.
- School of Biosecurity, Biotechnical and Laboratory Science, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda.
- Infectious Diseases Research Collaboration, Makerere University, Kampala, Uganda.
- Infectious Disease Institute, Makerere University, Kampala, Uganda.
ORCID-Profile: Martin Kamilo Angwe, Denis Omali, Moses Ocan
Förderung
- FIC NIH HHS
- National Institutes of Health
- European and Developing Countries Clinical Trials Partnership
Zitieren
APA
Angwe, M. K., Mwebaza, N., Nsobya, S. L., Kiguba, R., Vudriko, P., Dralabu, S., Omali, D., Tumwebaze, M. A., & Ocan, M. (2025). CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine. PLOS One. https://doi.org/10.1371/journal.pone.0322918
Vancouver
Angwe MK, Mwebaza N, Nsobya SL, Kiguba R, Vudriko P, Dralabu S, et al. CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine. PLOS One. 2025. doi:10.1371/journal.pone.0322918
BibTeX
@article{Angwe2025,
author = {Angwe, Martin Kamilo and Mwebaza, Norah and Nsobya, Sam Lubwama and Kiguba, Ronald and Vudriko, Patrick and Dralabu, Saviour and Omali, Denis and Tumwebaze, Maria Agnes and Ocan, Moses},
title = {CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322918}
}
EUVIMED